Drugs & TargetsFree FDA issues guidance on investigational in vitro diagnostics in oncology trials April 20, 2018Vol.44 No.16
Drugs & Targets Rucaparib approved for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer April 13, 2018Vol.44 No.15
Drugs & Targets FDA finalizes guidances to accelerate development of Next Gen sequencing April 13, 2018Vol.44 No.15
Drugs & Targets MD Anderson, Nanobiotix to collaborate on preclinical research combining NBTXR3, nivolumab April 13, 2018Vol.44 No.15
Drugs & TargetsFree EC expands XGEVA indications for prevention of skeletal events in multiple myeloma April 06, 2018Vol.44 No.14
Drugs & TargetsFree NCI launches resource for specimens and data from clinical trials April 06, 2018Vol.44 No.14
Drugs & TargetsFree Boehringer Ingelheim, OSE collaborate to develop checkpoint inhibitor April 06, 2018Vol.44 No.14
Drugs & Targets FDA gives accelerated approval for Blincyto for ALL patients with minimal residual disease March 30, 2018Vol.44 No.13
Drugs & Targets Enfortumab vedotin gets breakthrough designation in urothelial cancer March 30, 2018Vol.44 No.13
